Prognostic capacity of Systemic Inflammation Response Index (SIRI) in patients with head and neck squamous cell carcinoma

Abstract

Background: Inflammation and immune evasion are associated with carcinogenesis. Systemic Inflammation Response Index (SIRI) has been proposed as a pretreatment peripheral blood biomarker. The aim of this study is to analyze its prognostic capacity in head and neck squamous cell carcinomas (HNSCC). Methods: We performed a retrospective study in 824 patients with HNSCC. SIRI was calculated by neutrophils*monocytes/lymphocytes. Using a recursivepartitioning analysis considering disease-specific survival (DSS) as dependent variable, three categories were defined according to SIRI value. Results: Males, patients with history of toxic consumption, oropharyngeal or hypopharyngeal tumors, and advanced tumors had a significantly higher SIRI value. As SIRI increased, a significant decrease in DSS was observed. In a multivariable analysis, SIRI was an independent predictor of DSS. Moreover, SIRI was a significant predictor of local, regional, and distant recurrence-free survival. Conclusions: SIRI has independent prognostic capacity in HNSCC. Patients with higher SIRI have a significant decrease in DSS.

Systemic Inflammation Response Index Is a Predictor of Poor Survival in Locally Advanced Nasopharyngeal Carcinoma: A Propensity Score Matching Study

“…Qi Q et al ( 30 ) conducted a cohort study of patients with advanced pancreatic carcinoma who received palliative chemotherapy, and found that SIRI≥1.8 had a shorter time to progression (HR: 2.348; 95% CI: 1.559-3.535; p =0.003) and shorter OS (HR: 2.789; 95% CI: 1.897-4.121; p < 0.001). In patients with head and neck squamous cell carcinomas, research showed that compared with SIRI<1.1, patients with SIRI between 1.10 and 2.80 had a 1.92 times higher risk of disease-specific death (95% CI: 1.33‐2.82; p =0.001), and patients with SIRI >2.80 had a 2.89 times higher risk (95% CI: 1.86‐4.42; p =0.0001), SIRI was an independent predictor of disease-specific survival ( 31 ). SIRI was also investigated in patients with NPC.…”

Immune Cell Infiltrates and Neutrophil-to-Lymphocyte Ratio in Relation to Response to Chemotherapy and Prognosis in Laryngeal and Hypopharyngeal Squamous Cell Carcinomas

“…An elevated NLR indicates systemic inflammation. The inflammatory response associated with cancer plays a key role in clinical outcomes [ 14 , 15 , 16 , 25 ]. Cancer cells recruit and activate leukocytes, and although the precise role of neutrophils within the TME remains controversial, they appear to facilitate tumor progression.…”

“…Systemically, this inflammatory response is manifested by an increase in circulating neutrophils, monocytes, and platelets. In addition, this state of chronic inflammation reduces the number of T-lymphocytes available, capable of acting against tumor cells [ 14 ]. Thus, the neutrophil-to-lymphocyte ratio (NLR) obtained from the peripheral blood count is used as a marker of the relationship between the inflammatory response and the immune response to cancer.…”

The aspartate aminotransaminase/alanine aminotransaminase (De Ritis) ratio predicts sensitivity to radiotherapy in head and neck carcinoma patients

“…Several studies have found a relationship between commonly used blood‐based parameters and prognosis in patients with head and neck squamous cell carcinomas (HNSCC). Some of these parameters include the neutrophil‐to‐lymphocyte ratio, 1 the systemic inflammation response index (SIRI), based on a combined analysis of the neutrophils, monocytes and lymphocytes count, 2 or the Glasgow prognostic score, that includes the C‐reactive protein level to reflect the systemic inflammation status and the serum albumin level to reflect nutritional status 3 . To have markers with prognostic capacity readily available from a simple peripheral blood test makes them attractive parameters to be used for better individualized risk evaluation.…”